Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

被引：0
|
作者：
Flinn, Ian [1 ]
Brunvand, Mark [2 ]
Dyer, Martin J. S. [3 ]
Hillman, Peter [4 ]
Jones, Jeffrey [5 ]
Lymp, James [6 ]
Elhamy, Mostafa [6 ]
Vosganian, Gregory [6 ]
Huang, Jane [6 ]
Kipps, Thomas J. [7 ]
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Colorado Blood Canc Inst, Denver, CO USA
[3] Univ Leicester, Leicester, Leics, England
[4] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England
[5] Ohio State Univ, Sch Med, Columbus, OH 43210 USA
[6] Genentech Inc, San Francisco, CA 94080 USA
[7] Univ Calif San Diego, La Jolla, CA 92093 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] PHASE I STUDY OF ABT-199 (GDC-0199) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA: RESPONSES OBSERVED IN DIFFUSE LARGE B-CELL (DLBCL) AND FOLLICULAR LYMPHOMA (FL) AT HIGHER COHORT DOSES
    Davids, M. S.
    Seymour, J. F.
    Gerecitano, J. F.
    Kahl, B. S.
    Pagel, J. M.
    Wierda, W. G.
    Anderson, M. A.
    Rudersdorf, N. K.
    Gressick, L. A.
    Montalvo, N. P.
    Yang, J.
    Zhu, M.
    Dunbar, M.
    Cerri, E.
    Enschede, S. H.
    Humerickhouse, R. A.
    Roberts, A. W.
    HAEMATOLOGICA, 2014, 99 : 525 - 525
  • [42] Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
    Seymour, John F.
    Davids, Matthew S.
    Pagel, John M.
    Kahl, Brad S.
    Wierda, William G.
    Miller, Thomas P.
    Gerecitano, John F.
    Kipps, Thomas J.
    Anderson, Mary-Ann
    Huang, David C. S.
    Rudersdorf, Nikita K.
    Gressick, Lori A.
    Montalvo, Nicholas P.
    Yang, Panning
    Busman, Todd A.
    Dunbar, Martin
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod A.
    Roberts, Andrew W.
    BLOOD, 2013, 122 (21)
  • [43] Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase Ill Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions
    Fischer, Kirsten
    Fink, Anna-Maria
    Bishop, Helen
    Dixon, Mark
    Bahlo, Jasmin
    Chol, Michael Y.
    Weinkove, Robert
    Robinson, Sue
    Dreyling, Martin
    Seiler, Till
    Opat, Stephen
    Owen, Carolyn
    Lopez, Javier, Sr.
    Kutsch, Nadine
    Tausch, Eugen
    Ritgen, Matthias
    Humerickhouse, Rod A.
    Humphrey, Kathryn
    Wenger, Michael K.
    Goede, Valentin
    Eichhorst, Barbara
    Wendtner, Clemens-Martin
    Stilgenbauer, Stephan
    Kipps, Thomas J.
    Hallek, Michael
    BLOOD, 2015, 126 (23)
  • [44] Preliminary Safety and Efficacy Results From a Phase 2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
    Awan, Farrukh T.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 6 - 8
  • [45] Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/ Refractory or Previously Untreated Chronic Lymphocytic Leukemia
    Stilgenbauer, Stephan
    Morschhauser, Franck
    Wendtner, Clemens-Martin
    Cartron, Guillaume
    Hallek, Michael
    Eichhorst, Barbara F.
    Kozloff, Mark
    Giever, Thomas A.
    Lozanski, Gerard
    Punnoose, Elizabeth A.
    Wang, Jue
    Hilger, James
    Mobasher, Mehrdad
    Salles, Gilles
    BLOOD, 2016, 128 (22)
  • [46] Phase 1b Results of a Phase 1b/2 Study of Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Jones, Jeffrey A.
    Woyach, Jennifer
    Awan, Farrukh T.
    Maddocks, Kami J.
    Whitlow, Thomas
    Ruppert, Amy S.
    Byrd, John C.
    BLOOD, 2016, 128 (22)
  • [47] The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study
    Davids, Matthew S.
    Roberts, Andrew W.
    Anderson, Mary Ann
    Pagel, John M.
    Kahl, Brad S.
    Gerecitano, John F.
    Darden, David E.
    Nolan, Cathy E.
    Gressick, Lori A.
    Yang, Jianning
    Chyla, Brenda J.
    Busman, Todd A.
    Graham, Alison M.
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod A.
    Seymour, John F.
    BLOOD, 2012, 120 (21)
  • [48] Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Bosch, Francesc
    Illmer, Thomas
    Turgut, Mehmet
    Cortelezzi, Agostino
    Lasserre, Susan F.
    Truppel-Hartmann, Anna
    Leblond, Veronique
    Foa, Robin
    Stilgenbauer, Stephan
    BLOOD, 2014, 124 (21)
  • [49] Initial Results of a Phase Ib Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Kim, Haesook T.
    Savell, Alexandra
    Santiago-Medero, Carlos
    Francoeur, Karen
    Abramson, Jeremy S.
    Jacobsen, Eric D.
    LaCasce, Ann S.
    Fisher, David C.
    Brown, Jennifer R.
    BLOOD, 2017, 130
  • [50] PRELIMINARY SAFETY DATA FROM THE PHASE 3B GREEN STUDY OF OBINUTUZUMAB (G) ALONE OR COMBINED WITH CHEMOTHERAPY FOR PREVIOUSLY UNTREATED OR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Leblond, V.
    Dilhuydy, M. S.
    Foa, R.
    Knauf, W.
    Montillo, M.
    Robinson, S.
    Stilgenbauer, S.
    Gresko, E.
    Lasserre, S.
    Bosch, F.
    HAEMATOLOGICA, 2016, 101 : 149 - 149
12345